Literature DB >> 12634506

Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.

Mikael Angehagen1, Doru Georg Margineanu, Elinor Ben-Menachem, Lars Rönnbäck, Elisabeth Hansson, Henrik Klitgaard.   

Abstract

The effect of the novel antiepileptic drug levetiracetam on caffeine (10 mM)-induced intracellular calcium ([Ca2+]i) response was investigated in rat hippocampal neurons in culture, with the aim of exploring the cellular mechanisms of this new drug. Levetiracetam significantly reduced caffeine-induced [Ca2+]i) response, with maximum inhibition at 32 microM. The R-enantiomer of levetiracetam, ucb L060, which is devoid of anticonvulsant activity, at 32 microM had no effect on caffeine-induced [Ca2+]i) response. Caffeine 10 mM also induced epileptiform field potentials in rat hippocampal slices : single stimuli evoked repetitive population spikes and spontaneous field bursts regularly occurred. Levetiracetam (32 microM) significantly inhibited the amplitudes and the number of caffeine-induced repeated population spikes and delayed the appearance of spontaneous bursts, while ucb L060 (32 microM) completely lacked anti-caffeine activity. These results suggest that the inhibition of caffeine-induced Ca release from intra-neuronal stores might be an excitability-reducing effect of levetiracetam, contributing to its antiepileptic activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634506     DOI: 10.1097/00001756-200303030-00035

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

1.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

2.  Hypothermia reduces calcium entry via the N-methyl-D-aspartate and ryanodine receptors in cultured hippocampal neurons.

Authors:  Kristin F Phillips; Laxmikant S Deshpande; Robert J DeLorenzo
Journal:  Eur J Pharmacol       Date:  2012-10-17       Impact factor: 4.432

Review 3.  The Use of Caffeine by People with Epilepsy: the Myths and the Evidence.

Authors:  Prisca R Bauer; Josemir W Sander
Journal:  Curr Neurol Neurosci Rep       Date:  2019-05-14       Impact factor: 5.081

Review 4.  Levetiracetam: a review of its use in epilepsy.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

5.  Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture.

Authors:  Nisha Nagarkatti; Laxmikant S Deshpande; Robert J DeLorenzo
Journal:  Neurosci Lett       Date:  2008-03-21       Impact factor: 3.046

6.  Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.

Authors:  Pascal E Sanchez; Lei Zhu; Laure Verret; Keith A Vossel; Anna G Orr; John R Cirrito; Nino Devidze; Kaitlyn Ho; Gui-Qiu Yu; Jorge J Palop; Lennart Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

7.  Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion.

Authors:  Yue Zhang; Ying Li; Lian Zuo; Huan Bao; Xiahong Xu; Junjie Hao; Xin Wang; Gang Li
Journal:  Mol Neurobiol       Date:  2015-10-10       Impact factor: 5.590

8.  Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesis.

Authors:  Dustin Shilling; Marioly Müller; Hajime Takano; Don-On Daniel Mak; Ted Abel; Douglas A Coulter; J Kevin Foskett
Journal:  J Neurosci       Date:  2014-05-14       Impact factor: 6.167

9.  Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures.

Authors:  Carol M Ulloa; Allen Towfigh; Joseph Safdieh
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

10.  The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion.

Authors:  Ornella Cuomo; Vincenzo Rispoli; Antonio Leo; Giovanni Bosco Politi; Antonio Vinciguerra; Gianfranco di Renzo; Mauro Cataldi
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.